Cargando…

Treatment of Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. In the past, treatment was aimed at minimizing inflammation and slowing the progression of inflammation to fibrosis. However, the underlying...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuserewa, Sherif T, Duff, Richard, Becker, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245298/
https://www.ncbi.nlm.nih.gov/pubmed/34239792
http://dx.doi.org/10.7759/cureus.15360
_version_ 1783716087717691392
author Abuserewa, Sherif T
Duff, Richard
Becker, Gregory
author_facet Abuserewa, Sherif T
Duff, Richard
Becker, Gregory
author_sort Abuserewa, Sherif T
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. In the past, treatment was aimed at minimizing inflammation and slowing the progression of inflammation to fibrosis. However, the underlying lesion in IPF may be more fibrotic than inflammatory, explaining why few patients respond to anti-inflammatory therapies and the prognosis remains poor. In this review of literature, we will be focusing on main lines of treatment including current medications, supportive care, lung transplantation evaluation, and potential future strategies of treatment.
format Online
Article
Text
id pubmed-8245298
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-82452982021-07-07 Treatment of Idiopathic Pulmonary Fibrosis Abuserewa, Sherif T Duff, Richard Becker, Gregory Cureus Internal Medicine Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. In the past, treatment was aimed at minimizing inflammation and slowing the progression of inflammation to fibrosis. However, the underlying lesion in IPF may be more fibrotic than inflammatory, explaining why few patients respond to anti-inflammatory therapies and the prognosis remains poor. In this review of literature, we will be focusing on main lines of treatment including current medications, supportive care, lung transplantation evaluation, and potential future strategies of treatment. Cureus 2021-05-31 /pmc/articles/PMC8245298/ /pubmed/34239792 http://dx.doi.org/10.7759/cureus.15360 Text en Copyright © 2021, Abuserewa et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Abuserewa, Sherif T
Duff, Richard
Becker, Gregory
Treatment of Idiopathic Pulmonary Fibrosis
title Treatment of Idiopathic Pulmonary Fibrosis
title_full Treatment of Idiopathic Pulmonary Fibrosis
title_fullStr Treatment of Idiopathic Pulmonary Fibrosis
title_full_unstemmed Treatment of Idiopathic Pulmonary Fibrosis
title_short Treatment of Idiopathic Pulmonary Fibrosis
title_sort treatment of idiopathic pulmonary fibrosis
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245298/
https://www.ncbi.nlm.nih.gov/pubmed/34239792
http://dx.doi.org/10.7759/cureus.15360
work_keys_str_mv AT abuserewasherift treatmentofidiopathicpulmonaryfibrosis
AT duffrichard treatmentofidiopathicpulmonaryfibrosis
AT beckergregory treatmentofidiopathicpulmonaryfibrosis